Quote | Palisade Bio Inc. (NASDAQ:PALI)
Last: | $4.35 |
---|---|
Change Percent: | -4.19% |
Open: | $4.7 |
Close: | $4.54 |
High: | $4.7 |
Low: | $4.35 |
Volume: | 11,257 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Palisade Bio Inc. (NASDAQ:PALI)
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...
Message Board Posts | Palisade Bio Inc. (NASDAQ:PALI)
Subject | By | Source | When |
---|---|---|---|
bs you out with a loss mtf | peterus | investorshub | 04/06/2023 8:09:43 PM |
Out with small win,next | 81vette | investorshub | 04/06/2023 3:59:05 PM |
Beautiful bottom nab,big accumulation started on 30th, institutional/insider | 81vette | investorshub | 04/05/2023 4:10:49 PM |
News out,phase 3 trial,float 1.36m,short 10%(152,545 shares)ZERO BORROW,(no | 81vette | investorshub | 04/05/2023 4:04:38 PM |
I like the chart. | traderbbc1 | investorshub | 04/04/2023 11:08:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisad...